

Alameda Alliance for Health
1240 South Loop Road
Alameda, CA 94502

Location: Cisco Webex, (408)418-9388
Meeting ID: 146 171 2791
Password: AAHPharmacy

IMPORTANT PUBLIC HEALTH AND SAFETY MESSAGE REGARDING PARTICIPATION AT ALAMEDA ALLIANCE FOR HEALTH COMMITTEE MEETINGS

AS A RESULT OF THE COVID-19 VIRUS, AND RESULTING ORDERS AND DIRECTION FROM THE PRESIDENT OF THE UNITED STATES, THE GOVERNOR OF THE STATE OF CALIFORNIA, AND THE ALAMEDA COUNTY HEALTH OFFICER, THE PUBLIC WILL NOT BE PERMITTED TO PHYSICALLY ATTEND THE ALAMEDA ALLIANCE FOR HEALTH MEETING TO WHICH THIS AGENDA APPLIES.

YOU MAY SUBMIT COMMENTS ON ANY AGENDA ITEM OR ON ANY ITEM NOT ON THE AGENDA, IN WRITING VIA MAIL TO "ATTN: ALLIANCE PHARMACEUTICAL AND THERAPEUTICS COMMITTEE" 1240 SOUTH LOOP ROAD, ALAMEDA, CA 94502; OR THROUGH E-COMMENT AT aragadio@alamedaalliance.org. YOU MAY WATCH THE MEETING LIVE BY LOGGING IN VIA COMPUTER AT THE FOLLOWING LINK <https://alamedaalliance.webex.com/alamedaalliance> OR MAY LISTEN TO THE MEETING BY CALLING IN TO THE FOLLOWING TELEPHONE NUMBER: 1-408-418-9388. IF YOU USE THE LINK AND PARTICIPATE VIA COMPUTER, YOU MAY, THROUGH THE USE OF THE CHAT FUNCTION, REQUEST AN OPPORTUNITY TO SPEAK ON ANY AGENDIZED ITEM, INCLUDING GENERAL PUBLIC COMMENT. YOUR REQUEST TO SPEAK MUST BE RECEIVED BEFORE THE ITEM IS CALLED ON THE AGENDA. IF YOU PARTICIPATE BY TELEPHONE, YOU MUST SUBMIT ANY COMMENTS VIA THE E-COMMENT EMAIL ADDRESS DESCRIBED ABOVE.

PLEASE NOTE: THE ALAMEDA ALLIANCE FOR HEALTH IS MAKING EVERY EFFORT TO FOLLOW THE SPIRIT AND INTENT OF THE BROWN ACT AND OTHER APPLICABLE LAWS REGULATING THE CONDUCT OF PUBLIC MEETINGS, IN ORDER TO MAXIMIZE TRANSPARENCY AND PUBLIC ACCESS. IT WOULD BE APPRECIATED IF COMMUNICATIONS OF PUBLIC COMMENTS RELATED TO ITEMS ON THE AGENDA, OR ITEMS NOT ON THE AGENDA, ARE PROVIDED PRIOR TO THE COMMENCEMENT OF THE MEETING. IF THAT IS NOT POSSIBLE, EVERY EFFORT WILL BE MADE TO ATTEMPT TO REVIEW E-COMMENTS DURING THE COURSE OF THE MEETING. TOWARDS THIS END, THE CHAIR OF THE COMMITTEE WILL ENDEAVOR TO TAKE A BRIEF PAUSE BEFORE ACTION IS TAKEN ON ANY AGENDA ITEM TO ALLOW THE COMMITTEE CLERK TO REVIEW E-COMMENTS, AND SHARE ANY E-COMMENTS RECEIVED DURING THE MEETING.

AGENDA

ITEM	DESCRIPTION	TIME	VOTE
I)	Call to order <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <ul style="list-style-type: none"> Agenda Overview 	2 min	-
II)	Informational Updates <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <ul style="list-style-type: none"> Pharmacy Carve Out Update Carve Out Expected Changes Upcoming DMHC Audit P&T Committee Member Roles 	15 min	-
III)	Pharmacy Utilization Reports (Quarter 3) <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <ul style="list-style-type: none"> Top 50 Drugs by Cost Top 100 PA Reviewed Drugs 	2 min	-

IV) E-Voting Material/Consent Agenda

The following items have been sent to the voting committee for review via E-voting

Natalee Felten, PharmD, Pharmacist, PerformRx

(All matters listed on the Consent Calendar are to be approved with one motion unless a member of the P&T Committee removes an item for separate action. Any consent calendar item for which separate action is requested shall be heard as the next Agenda item in closed session.)

Monographs/Class Reviews	Changes
Test strips (abbreviated)	• No change
SGLT2 Inhibitors	• No change
Rho immune globulins	• No change
Vitamin D analogs	• No change
Continuous glucose monitors	• No change
Methergine monograph	• No change
Medication Request Guidelines	Changes
Alosetron (Lotronex)	• Update the brand generic status
Oral and Non-Oral Contraceptives	• Change Depo-SubQ Provera status - PA coding was removed
Immunizations	• Remove Menomune – off market • Add MenQuadfi
Urinary Incontinence Agents	• Add statement “Any other agent for urinary incontinence”
HP Acthar Criteria	• Update name of the product remove “H.P.” • Correct spelling of “approved”
Criteria for Long-Acting Opioids	• Add Hysingla to Non-formulary list • Remove MorphaBond ER tablet – off market
Proton Pump Inhibitors (PPIs)	• Add “Any other non-formulary proton pump inhibitor medication or dosage formulation” to medications section
Isotretinoin capsules	• Add new medication Absorica LD
Lupron Depot and Lupron Depot-Ped	• Remove Lupron Depot 30mg – off market
Viberzi (eluxadoline)	• No changes
Agents for Atopic Dermatitis	• No changes
Thalomid (thalidomide)	• No changes
Endari	• No changes
Phosphate Binders	• No changes
Otezla (apremilast) for Behcet Disease	• No changes
Korlym (mifepristone)	• No changes
Step Therapy Exception	• No changes
Prior Authorization Exception	• No changes
Butorphanol (Stadol NS)	• No changes
Temazepam (Restoril)	• No changes
Oral Anti-Fungals	• No changes
Gattex (teduglutide)	• No changes
Ranolazine ER (Ranexa)	• No changes
Growth Hormone	• No changes

10
min

EV
(on
each
topic)

Interim Formulary changes
<ul style="list-style-type: none"> • See p. XX in packet
Pharmacy Policy & Procedure Updates
<ul style="list-style-type: none"> • No updates at this time
P&T Meeting Minutes
<ul style="list-style-type: none"> • P&T Meeting Minutes Q3 September 15, 2020

ADJOURN TO CLOSED SESSION (Pursuant to California Government Code Title 5, §54954.5(h))

Discussion will Concern: Review and Recommendations to changes to the AAH Formulary and utilization management for selected drug classes
Estimated Date of Public Disclosure: 9/15/2020 (formulary changes only; no trade secrets will be disclosed).

V) New Business

Natalee Felten, PharmD, Pharmacist, PerformRx

- Physician Administered Drug (PAD) Medication Request Guideline Document
 - New**
 - Tepezza
 - Vilterso (viltolarsen)
 - Neuromyelitis Optica Spectrum Disorder (NMOSD) Agents
 - Veklury (remdesivir)
 - Revised**
 - Complement Inhibitors
 - Anti-CD20 Monoclonal Antibodies
 - Iron-containing Products
 - Anti-CD19 CAR-T Immunotherapies
 - Healthcare professional (HCP) administered/IV DMTs for Multiple Sclerosis (MS)

VI) Class Reviews, Monographs, and Recommendations

Natalee Felten, PharmD, Pharmacist, PerformRx

Rahel Negash, PharmD, Pharmacist, Alameda Alliance

1. Topical Antifungals
2. Methylxanthine bronchodilators
3. Multiple Sclerosis agents

45
min

V
(on
each
topic)

VII) Medication Request Guidelines

Rahel Negash, PharmD, Pharmacist, Alameda Alliance

Natalee Felten, PharmD, Pharmacist, PerformRx

1. Intranasal steroids
2. Defirasirox
3. Entresto (sacubitril/valsartan)
4. Fentanyl Citrate
5. Injectable Methotrexate
6. Topical Diclofenac
7. Topiramate (Topamax) sprinkles
8. Specialty Biological Agents for Ankylosing Spondylitis

VIII) Summary of Closed Session

Helen Lee, PharmD, MBA, Senior Pharmacy Director – Alameda Alliance

RECONVENE IN OPEN SESSION

ITEM	DESCRIPTION	TIME	VOTE
IX)	Informational Updates on New Developments in Pharmacy <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i> <ul style="list-style-type: none"> New Product Review 	2 min	-
X)	Old Business <ul style="list-style-type: none"> None 	0 min	
XI)	Public Comment	0 min	-
XII)	Adjournment <ul style="list-style-type: none"> P&T Committee Member Forms 		

ACTION / FOLLOW-UP ITEMS

ITEM	DUE DATE	RESPONSIBLE

FUTURE P&T MEETINGS

NEXT MEETING	2021 P&T MEETINGS
March 16th, 2021	June 15th, 2021
	September 21 st , 2021

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. If you wish to speak on a matter on the agenda, you will have the opportunity to do so in the order determined by the Chair. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

Note: Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Helen Lee at 510-747- 6241 or hlee@alamedaalliance.org at least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy thille benefits of the meeting.